Pagenax 120 mg contains brolucizumab, a next-generation monoclonal antibody fragment developed to treat certain eye conditions that lead to vision loss. It is specifically used in retinal diseases where abnormal blood vessel growth and fluid leakage occur in the eye. What makes brolucizumab stand out is its small molecular size, allowing for higher concentration delivery and longer duration of action with fewer injections. Pagenax offers a more convenient dosing schedule while helping patients preserve vision and improve retinal health.

Mechanism of Action

Brolucizumab works by targeting and neutralising a protein in the body called vascular endothelial growth factor A, commonly referred to as VEGF A. VEGF A plays a central role in promoting the formation of new, often leaky, blood vessels under the retina. In diseases like wet age-related macular degeneration, this abnormal vessel growth can lead to fluid buildup and vision impairment. By blocking VEGF A, Pagenax helps reduce fluid leakage and swelling, preventing further vision damage and even improving clarity over time.

Uses

Pagenax is primarily prescribed for:

• Neovascular (wet) age-related macular degeneration

• Diabetic macular edema (under evaluation or approval in select countries)

These are serious eye conditions where abnormal blood vessels grow in the retina and may leak fluid, leading to rapid and severe vision loss if not treated. Pagenax helps control the disease and often restores a degree of vision when administered appropriately.

Adverse Effects

Common side effects

• Eye pain or discomfort after injection

• Blurred vision

• Redness of the eye

• Small floaters or spots in vision

• Sensation of something in the eye